Prescriber Scope of Practice for General Psychiatry

You’ve built a solid psychiatric practice, and now you’re eyeing telehealth — or maybe you’re already doing it and wondering if you’re fully compliant. Either way, there’s one question keeping you up at night: Can I legally prescribe Adderall, benzos, or buprenorphine via video calls?

The short answer: Yes, through the end of 2026 — and likely beyond, though the rules are changing.

Let’s cut through the noise. Federal telehealth flexibilities for controlled substances have been extended through December 31, 2026, meaning you can continue prescribing Schedule II–V medications via telemedicine without requiring an in-person exam first. But here’s the catch: the DEA is finalizing permanent rules that will reshape how this works, and state laws add another layer of complexity that varies wildly depending on where your patients are located.

If you’re a psychiatrist or PMHNP trying to grow your practice through telehealth, understanding these regulations isn’t optional — it’s the foundation of compliant, sustainable growth. Here’s what you need to know right now.

The Current State of Federal Telehealth Prescribing (Through 2026)

What’s Actually Allowed Right Now

As of February 2026, the DEA and HHS have extended COVID-era telehealth prescribing flexibilities through the end of the year. This means:

• You can prescribe Schedule II–V controlled substances via telemedicine to both new and existing patients without an initial in-person exam
• The evaluation must be conducted via real-time, two-way audio-visual technology (video call) to establish a legitimate patient-provider relationship
• Standard of care still applies — you need a thorough psychiatric evaluation, appropriate diagnosis, treatment plan, and documentation just as you would in person

This extension exists because the DEA recognizes that abruptly ending telehealth flexibility would disrupt care for millions of patients, particularly in mental health. However, this is explicitly a temporary measure while permanent rules are finalized.

The Ryan Haight Act: Why This Matters

Before COVID, the Ryan Haight Act of 2008 required at least one in-person medical evaluation before prescribing controlled substances via the internet. The law was designed to combat ‘pill mills’ operating online, but it also created a massive barrier to legitimate telehealth.

During the pandemic, federal emergency authority suspended this requirement. That suspension has been extended multiple times and now runs through December 31, 2026. Once it expires (or when the DEA finalizes new rules), the landscape will shift again.

What Permanent Rules Are Coming

The DEA has proposed three new telemedicine rules expected to take effect in 2026 or early 2027:

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA is creating a ‘Special Telemedicine Prescriber Registration’ that will allow qualified providers to prescribe controlled substances to new patients via telehealth without ever requiring an in-person visit.

Here’s what matters for psychiatrists:

• Psychiatrists will be explicitly eligible for this special registration to prescribe Schedule II drugs (like stimulants for ADHD) via telehealth
• Other eligible specialties include hospice/palliative care physicians and pediatricians (for limited circumstances)
• Any qualified prescriber can get the registration for Schedule III–V substances
• Telehealth platforms will be required to register with the DEA for the first time
• A national PDMP system will be implemented to track prescriptions across states

This is huge: it means board-certified psychiatrists could potentially prescribe Adderall or Ritalin for ADHD via telehealth indefinitely, with no in-person requirement, once they obtain this special registration.

2. Buprenorphine Expansion via Telehealth

The DEA is proposing to allow providers to initiate buprenorphine for opioid use disorder through telemedicine (including audio-only) for up to 6 months before requiring an in-person visit.

This matters if you treat addiction:

• You can start and manage buprenorphine treatment entirely via telehealth for 180 days
• After 6 months, an in-person evaluation is required to continue treatment
• Audio-only is explicitly permitted for buprenorphine (phone calls count)

Combined with the elimination of the X-waiver in 2023, this makes addiction treatment significantly more accessible.

3. VA Continuity of Care Rule

A third rule streamlines care within the VA system — if a patient had an in-person exam with any VA clinician, any VA telehealth provider can prescribe controlled substances via telemedicine. This is less relevant to private practice but signals the DEA’s broader acceptance of telehealth models.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Prescribing Rules: Where It Gets Complicated

Federal law sets the floor, but states can impose stricter requirements. And they do. Here’s what you need to know for the most common states where psychiatrists practice telehealth.

California: Wide Open (With PDMP Requirements)

California is one of the most telehealth-friendly states for psychiatrists:

• No in-person exam required — you can establish a patient relationship via video
• No special restrictions on controlled substance prescribing via telehealth beyond federal law
• CURES PDMP check is mandatory — you must check California’s prescription monitoring database before prescribing any Schedule II–IV controlled substance for the first time, and every 4 months thereafter during ongoing treatment
• 100% e-prescribing required since January 2022 (paper scripts are essentially banned)
• NP independence is coming — experienced PMHNPs can practice independently starting in 2023 in group settings, with full independent practice (including opening private practices) allowed by 2026

Bottom line: If your patients are in California, you have maximum flexibility as long as you’re checking CURES and e-prescribing.

Texas: Psychiatrists Yes, NPs No (For Schedule II)

Texas has telehealth-friendly laws for physicians, but restrictive rules for advanced practice providers:

• Psychiatrists can prescribe controlled substances via telehealth using real-time video under the same standard as in-person care
• PMHNPs and PAs cannot prescribe Schedule II drugs (like Adderall or Ritalin) outside of hospital or hospice settings — this is a state law limitation, not a telehealth-specific rule
• Texas PDMP check is mandatory for opioids, benzodiazepines, barbiturates, and carisoprodol before prescribing
• Chronic pain exception — Texas prohibits prescribing controlled substances for chronic pain via telemedicine without at least one in-person visit (doesn’t typically affect psychiatry)

Bottom line: If you’re a Texas psychiatrist, you’re fine. If you’re a PMHNP treating ADHD patients in Texas, you’ll need a supervising physician to write those prescriptions.

Florida: Psychiatric Exception Saves the Day

Florida has strict controlled substance laws but carved out an exception for psychiatry:

• Schedule II drugs cannot be prescribed via telehealth unless it’s for: (1) psychiatric disorder treatment, (2) inpatient hospital care, (3) hospice, or (4) nursing home care
• This means you can prescribe Adderall for ADHD or other psychiatric Schedule II meds via telehealth in Florida — the psychiatric exception explicitly covers you
• Out-of-state providers can register as Florida telehealth providers without obtaining a full Florida license (though controlled substance prescribing is limited to the same exceptions)
• E-FORCSE PDMP check required before prescribing any controlled substance to patients age 16+
• PMHNPs must have a collaborative agreement with a supervising physician (Florida does not grant independent practice to psychiatric NPs)

Bottom line: Florida’s ‘psychiatric exception’ is critical — document that your Schedule II prescriptions are for mental health treatment, and you’re compliant.

New York: Strict PDMP, But Otherwise Flexible

New York combines telehealth flexibility with the nation’s strictest PDMP requirements:

• No in-person exam required — video evaluation establishes a valid patient relationship
• I-STOP law (NY PDMP) check is mandatory before prescribing any Schedule II, III, or IV controlled substance — every single time
• 100% e-prescribing required for all prescriptions (controlled and non-controlled) since 2016
• Experienced PMHNPs (>3,600 clinical hours) can practice independently including prescribing controlled substances

Bottom line: New York wants you to check the PDMP religiously, but otherwise doesn’t restrict telehealth prescribing.

Pennsylvania: Standard of Care Rules, But No Specific Law

Pennsylvania doesn’t have comprehensive telehealth legislation yet (as of 2026), but telehealth is widely accepted:

• Standard of care applies — video evaluation can establish a patient relationship
• PA PDMP check required before prescribing opioids or benzodiazepines (initial and ongoing)
• PMHNPs need collaborative agreements with at least two physicians for prescriptive authority; can prescribe Schedule II for up to 30 days, Schedule III–IV for up to 90 days
• E-prescribing required for controlled substances since 2019

Bottom line: Pennsylvania defers to federal law and professional judgment — just ensure thorough documentation.

Illinois: Full Practice for Experienced NPs (With Limits)

Illinois allows PMHNP independence but with conditions:

• Full Practice Authority available for PMHNPs with 4,000 clinical hours and additional training
• Even with full practice authority, NPs must have a physician ‘consultation relationship’ to prescribe benzodiazepines or Schedule II opioids (30-day supply limit without consultation)
• IL PDMP check mandatory before prescribing opioids (and recommended for other controlled substances)
• E-prescribing required for all controlled substances since January 2023

Bottom line: Illinois NPs have significant autonomy, but stimulant and benzo prescribing still requires physician involvement.

Psychiatrist vs. PMHNP Scope: What You Can Actually Do

Psychiatrists (MD/DO): Full Authority Everywhere

If you’re a licensed psychiatrist, your scope is straightforward:

• Full independent practice authority in all 50 states (just need the appropriate state medical license)
• Unrestricted prescribing authority for all controlled substances within your scope of practice
• No supervision requirements — you’re accountable only to your state medical board and DEA registration

The only limitations you face are state-specific telehealth or prescribing rules (like Florida’s psychiatric exception requirement or California’s PDMP mandate), not restrictions on your professional authority.

PMHNPs: State-Dependent and Complex

If you’re a psychiatric nurse practitioner, your scope varies dramatically by state:

Full Practice States (After Experience):

• California — Full independence after 3 years in supervised setting (by 2026)
• New York — Full independence after 3,600 clinical hours
• Illinois — Full Practice Authority license available after 4,000 hours (with consultation requirements for certain meds)

Restricted Practice States:

• Texas — Physician supervision always required; cannot prescribe Schedule II outside hospital/hospice
• Florida — Collaborative agreement required; no independent practice for psychiatric NPs
• Pennsylvania — Collaborative agreement with two physicians required for prescriptive authority

The Reality: If you’re a PMHNP building a telehealth practice, you need to either:

1. Practice only in states where you have full authority
2. Partner with a supervising physician in restricted states
3. Work with a platform (like Klarity Health) that handles these collaborative arrangements for you

The Economics of Compliant Telehealth Prescribing

Here’s the part most articles skip: compliance costs money, and doing it yourself is expensive.

The DIY Route: Higher Cost Than You Think

If you want to build your own multi-state telehealth practice while staying compliant, you’re looking at:

• State licensure fees — $300–800 per state, annually
• DEA registration — $731 every 3 years (federal), plus separate registrations in each state where you prescribe controlled substances
• PDMP registration — separate in each state (usually free, but time-consuming)
• Malpractice insurance — additional riders for telehealth and multi-state practice ($2,000–5,000+ annually)
• E-prescribing platform — DEA-compliant two-factor authentication system ($200–500/month)
• HIPAA-compliant telehealth platform — another $100–300/month
• Legal consultation — reviewing state-specific requirements ($200–400/hour)
• Staff time — managing licensing renewals, PDMP checks, documentation protocols

By the time you’re licensed and compliant in 3–4 states, you’re spending $10,000–15,000+ annually just on infrastructure before you see a single patient.

Then there’s patient acquisition. Most solo providers attempt:

• Google Ads — $15–40 per click for mental health keywords, with 2–5% conversion to booked appointments (realistic cost per booked patient: $300–800)
• SEO — 6–12 months of consistent investment ($2,000–5,000/month for agency or significant DIY time) before meaningful patient flow
• Psychology Today and directories — $30–100/month per listing, where you compete with hundreds of other providers on the same page

Most providers trying the DIY route spend $3,000–5,000/month on marketing with uncertain results — and that’s after they’ve invested months building the infrastructure.

The Platform Model: Pay Only When You See Patients

This is where platforms like Klarity Health change the economics entirely.

Instead of upfront marketing spend and monthly subscriptions with no guarantee of patients:

• No upfront costs — Klarity handles licensing verification, credentialing, and compliance infrastructure
• Pay per appointment — you pay a standard listing fee per new patient lead (similar to Zocdoc’s model), but only when a qualified patient actually books with you
• Pre-qualified patients — matched to your specialty (ADHD, anxiety, depression) and availability
• Built-in telehealth platform — HIPAA-compliant, DEA-ready, no separate subscription needed
• Both insurance and cash-pay flow — diversified patient base
• Multi-state infrastructure — if you’re licensed in multiple states, Klarity routes patients to you automatically

The ROI calculation is simple: Instead of gambling $3,000–5,000/month on marketing that might not work, you pay only when you see a patient. If you want to see 20 new patients a month, you pay for 20. If you want 50, you pay for 50. Zero wasted ad spend, zero months of SEO investment with no return.

For many providers — especially those starting out, scaling up, or who don’t want to become marketing experts — the platform model eliminates financial risk entirely while ensuring full regulatory compliance.

Compliance Best Practices: How to Prescribe Controlled Substances Safely via Telehealth

Regardless of whether you’re solo or on a platform, here’s how to stay compliant:

1. Document Everything Like You Would In-Person

Your telehealth note should include:

• Chief complaint and history of present illness
• Past psychiatric history
• Medication history (including PDMP review findings)
• Mental status examination (document observations made via video)
• Diagnosis (using DSM-5 or ICD-10 criteria)
• Treatment plan and rationale for controlled substance prescribing
• Informed consent for telehealth and for controlled substance treatment
• Patient’s physical location during the visit (for licensure compliance)

The DEA and state boards expect the same standard of care as in-person. If anything, document more thoroughly to protect yourself.

2. Always Check the PDMP

Every state now requires PDMP checks for controlled substances. Make it automatic:

• Check before prescribing to a new patient
• Check periodically for ongoing patients (California requires every 4 months; other states vary)
• Document the check in your note (‘PDMP reviewed, no concerning patterns identified’)

If you find red flags (early refills, multiple prescribers, high-risk combinations), address them clinically. Document your decision-making.

3. Use the Right Technology

• Video-first for new patients — audio-only doesn’t meet the standard for most controlled substance prescribing (except buprenorphine under special rules)
• E-prescribe everything — most states mandate it, and it creates an audit trail
• HIPAA-compliant platform — Zoom isn’t enough; use a BAA-covered telehealth system
• Two-factor authentication for e-prescribing of controlled substances (DEA requirement)

4. Know When to Refer for In-Person Care

Telehealth isn’t appropriate for every patient:

• First-time benzodiazepine prescription in someone with substance use history → consider in-person eval
• Patient with medical comorbidities requiring physical exam → coordinate with PCP or refer
• Patient in crisis requiring higher level of care → coordinate emergency services

Clinical judgment still applies. The fact that you can prescribe via telehealth doesn’t mean you always should.

5. Stay Current on Regulatory Changes

The rules are still evolving. Subscribe to:

• DEA updates on telemedicine (register for notifications on dea.gov)
• Your state medical board or nursing board newsletters
• Professional association updates (APA, AANP, etc.)

When the DEA finalizes its permanent rules (likely late 2026 or early 2027), you’ll need to adapt quickly. That might mean:

• Applying for the Special Telemedicine Registration
• Documenting in-person exams at 6-month intervals for certain treatments
• Complying with new platform registration requirements

FAQ: Prescribing Controlled Substances via Telehealth

Can I prescribe Adderall to a new patient I’ve never seen in person via telehealth in 2026?

Yes, through December 31, 2026 under the current federal extension. After that, you may need a Special Telemedicine Registration (if you’re a psychiatrist) or must conduct an in-person exam (depending on final DEA rules). State law also matters — check your state’s specific requirements.

Do I need to be licensed in the state where the patient is located?

Yes, always. Telehealth is considered to occur where the patient is physically located. You must hold an active medical or nursing license in that state. Some states (like Florida) offer out-of-state telehealth registration, but you still need authority to practice there.

Can a PMHNP prescribe stimulants via telehealth?

It depends on the state. In New York or California, yes (if they have independent practice authority). In Texas or Florida, no — they need a supervising physician to prescribe Schedule II drugs. Check your state’s NP scope of practice laws.

What’s the difference between Schedule II and Schedule III–V for telehealth prescribing?

Schedule II drugs (stimulants, some opioids) face the strictest controls. Some states like Florida explicitly restrict Schedule II prescribing via telehealth except for psychiatric treatment. Schedule III–V drugs (like some anxiety meds, sleep aids) are generally less restricted. Always check state law.

Can I prescribe controlled substances via phone call (audio-only)?

Generally no, except for buprenorphine for opioid use disorder under specific circumstances. For most controlled substances, the DEA expects real-time audio-visual (video) evaluation to establish a proper patient relationship. Audio-only doesn’t meet the standard for stimulants, benzodiazepines, etc.

Do I need malpractice insurance that covers telehealth?

Yes. Ensure your malpractice policy explicitly covers telemedicine and extends to all states where you’re licensed and practicing. Some carriers require notification if you’re practicing in multiple states.

What happens if the DEA extension ends and I haven’t done in-person exams?

If the extension expires without new rules in place (unlikely — the DEA has committed to preventing disruption), you may need to transition patients to in-person visits or refer them to local providers. More likely, the DEA’s permanent rules will provide a pathway (like the Special Telemedicine Registration) before the extension ends.

How do I know if a telehealth platform is compliant?

Ask these questions:

• Is the platform HIPAA-compliant with a Business Associate Agreement?
• Does it support DEA-compliant e-prescribing with two-factor authentication?
• Does it verify provider licensure in each state?
• Does it have a process for PDMP checks?
• Will the platform itself register with the DEA when required?

If the platform can’t answer these, find a different one.

The Bottom Line: Prescribing Controlled Substances via Telehealth is Legal, Sustainable, and Growing

The regulatory landscape is complex, but the direction is clear: telehealth prescribing of controlled substances is here to stay.

For psychiatrists, the current extension through 2026 provides certainty, and the proposed DEA rules will likely create a permanent framework that recognizes your specialty’s unique role in managing conditions like ADHD, anxiety, and opioid use disorder via telemedicine.

For PMHNPs, your authority depends heavily on state law — but the trend is toward greater independence in more states over time.

The key to success is staying compliant while building a sustainable patient base. You can do this solo if you have the budget, time, and expertise to navigate licensing, marketing, and operations across multiple states. Or you can join a platform that handles the infrastructure and delivers qualified patients who need your expertise.

Either way, the opportunity is massive: psychiatric care is in desperate demand, telehealth has proven effective for mental health treatment, and controlled substance prescribing via telemedicine is not only legal — it’s becoming the standard of care.

Ready to grow your psychiatric practice with pre-qualified patients and full compliance support? Explore how Klarity Health’s platform connects psychiatrists and PMHNPs with patients who need medication management — without the marketing gamble or compliance headaches. You focus on clinical care; we handle the rest.

Sources and Citations

1. HHS Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ – hhs.gov, January 2, 2026

2. DEA Press Release: ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Medications While Protecting Patients’ – dea.gov, January 16, 2025

3. Florida Statutes §456.47: Use of Telehealth to Provide Services – leg.state.fl.us, 2025 edition

4. Akerman LLP: ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth’ – akerman.com, March 2023

5. SAMHSA: ‘Removal of DATA Waiver (X-Waiver) Requirement and New Training Requirements for Prescribing Medications for Opioid Use Disorder’ – samhsa.gov, Updated 2023

This content is for informational purposes only and does not constitute legal or medical advice. Regulations continue to evolve — always verify current requirements with your state medical/nursing board and the DEA before making prescribing decisions.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices